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During the last two decades, a number of approaches for the 
activation of the immune system against cancer has been 
developed. These include highly specific interventions, such 
as monoclonal antibodies, vaccines and cell-based therapies, 
as well as relatively unselective strategies, such as the 
systemic administration of adjuvants and immunomodulatory 
cytokines. Cytokines constitute a huge group of proteins that, 
taken together, regulate not only virtually all the aspects of 
innate and cognate immunity, but also several other cellular 
and organismal functions. Cytokines operate via specific 
transmembrane receptors that are expressed on the plasma 
membrane of target cells and, depending on multiple variables, 
can engage autocrine, paracrine or endocrine signaling 
pathways. Perhaps, the most appropriate term for defining 
the cytokine network is “pleiotropic”: cytokines are produced 
by—and operate on—multiple, often overlapping, cell types, 
triggering context-depend biological outcomes as diverse as 
cell proliferation, chemotaxis, differentiation, inflammation, 
elimination of pathogens and cell death. Moreover, cytokines 
often induce the release of additional cytokines, thereby 
engaging self-amplificatory or self-inhibitory signaling 
cascades. In this Trial Watch, we will summarize the biological 
properties of cytokines and discuss the progress of ongoing 
clinical studies evaluating their safety and efficacy as 
immunomodulatory agents against cancer.
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Introduction
The word “cytokine” (derived from a Greek term meaning “to set 
cells in motion”) is employed to describe a highly heterogeneous 
group of small signaling (glyco)proteins that nowadays includes 
more than 130 members.1,2 Cytokines are produced throughout 
the body by an incredible variety of distinct cells, encompass-
ing virtually all cellular components of the immune system as 
well as epithelial, endothelial and stromal cells. Cytokine-
delivered signals, which—depending on the context—can be 
autocrine, paracrine or endocrine, are transduced into biological 
outcomes thanks to specific receptors that are expressed on the 
surface of target cells.1,2 Perhaps, the most appropriate word to 
characterize the cytokine system is “pleiotropic:” taken together, 
cytokines exert highly diversified functions, yet in a partially 
overlapping and redundant fashion. Thus, cytokines can trig-
ger biological outcomes as diverse as proliferation, chemotaxis, 
differentiation, inflammation, elimination of pathogens and cell 
death. Moreover, cytokines very often stimulate the production 
and release of additional cytokines, de facto functioning as part 
of finely regulated and highly intertwined signaling cascades. 
Such a pleiotropism reflects not only the heterogeneous identity 
of cytokines as a group, but also (1) the existence of multiple 
receptors that can bind the same cytokine with different affinity 
(which are frequently expressed on different target cells), and (2) 
the fact that the biological activity of one cytokine on a specific 
target cell is highly influenced by the concomitant presence of 
additional cytokines.1,2© 2012 Landes Bioscience.
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A wide array of adverse conditions, encompassing inflamma-
tion, infection by pathogens and tumorigenesis, provokes the 
secretion of cytokines. In this context, cytokines underlie a host 
response that aims at minimizing the harmful effects of stress, 
favoring repair mechanisms and, eventually, restoring homeo-
stasis. Indeed, cytokines are often released in subsequent waves, 
and the terminal molecules of the cascade normally function to 
extinguish the stress response, along with the reestablishment of 
homeostasis. One prominent example of this biological behav-
ior is provided by the systemic response to the administration 
of lipopolysaccharide (LPS, mimicking widespread bacterial 
infection). In this model, a rapid secretion of tumor necrosis fac-
tor α (TNFα) precedes a wave of interleukin-1β (IL-1β), IL-6, 
IL-8, IL-17A, IL-18 and interferon γ (IFNγ) (all of which exert 
potent pro-inflammatory effects, at both local and system levels), 
followed by a relatively delayed secretion of anti-inflammatory 
IL-10.3-5 In some instances, however, repair mechanisms are 
inefficient and fail to resolve the cytokine-inducing stimulus, 
leading to persistent cytokine production and exacerbated tissue 
damage. This is particularly relevant for inflammation-driven 
carcinogenesis, as it implies that the sites of chronic inflamma-
tion are a source of potentially mutagenic chemicals (e.g., high 
levels of reactive oxygen species) as well as of cytokine cocktails 
that may promote survival, proliferation and angiogenesis.6,7 
Taken together, these observations suggest that the administra-
tion of immunomodulatory cytokines for eliciting an antitumor 
immune response should always be carefully weighted not only 
against their acute toxicity (in some cases resembling a state of 
severe infection) but also against the possibility to exacerbate 
inflammation-associated oncogenesis.6 In addition, some cyto-
kines are endowed with potent mitogenic functions, de facto pre-
cluding their use as anticancer agents (see below).
During the last three decades, there have been multiple 
attempts to classify cytokines based on structural and/or func-
tional parameters. Thus, at some stage, terms including “lympho-
kines,” “interleukins” and “chemokines” have been introduced to 
indicate cytokines that are produced by lymphocytes, cytokines 
that mediate the communication between leucocytes, and cyto-
kines that stimulate chemotaxis, respectively.1,2 Today, accord-
ing to the Kyoto Encyclopedia of Genes and Genomes (www.
genome.jp/kegg/), cytokines can be cataloged into nine main 
groups: (1) chemokines, small cytokines with chemotactic activi-
ties that can further be subdivided into C, CC, CXC and CX3C 
chemokines, depending on the number and arrangement of con-
served cysteine residues; (2) hematopoietic growth factors (or 
hematopoietins), i.e., cytokines with a prominent role in hema-
topoiesis, which can be further grouped—based on their respec-
tive receptors—into gp130 (IL6ST) shared, IL13RA1 shared, 
IL12RB1 shared, IL3RB (CSF2RB) shared, ILRG shared and 
others; (3) interleukin-1 family members; (4) interleukin-10 
family members; (5) interleukin-17 family members; (6) inter-
ferons (IFNs); (7) platelet-derived growth factor (PDGF) fam-
ily members; (8) transforming growth factor β (TGFβ) family 
members; and (9) tumor necrosis factors (Table 1).
Experts in the field of cytokine research would probably 
criticize many aspects of this relatively inaccurate but simple 
classification. Nevertheless, since our aim is not to dwell on the 
cytokine system in detail, we will use this scheme to provide 
a conceptual framework to our Trial Watch, in which we will 
briefly review the biological properties of cytokines and discuss 
the progress of ongoing (started after January 2008) clinical tri-
als investigating their safety and efficacy as immunomodulatory 
agents against cancer. In line with this objective, our Trial Watch 
will deliberately disregard the use of cytokines for hematopoietic 
reconstitution upon chemotherapy or transplantation. Of note, 
only 2 cytokines out of more than 130 are nowadays approved by 
FDA for anticancer therapy: IFNα2b and IL-2 (Table 2).
Chemokines
Chemokines are small (8–10 kDa) secreted proteins that share 
a highly conserved secondary structure and a distinguishing 
tetracysteine motif, constituting the basis of their systematic 
classification (see above). Chemokines have first been charac-
terized for their ability to stimulate the migration of cell types 
as diverse as neutrophils, monocytes, lymphocytes, eosinophils, 
fibroblasts and keratinocytes. However, it is now clear that 
chemokines, as a family, contribute to a wide array of physi-
ological and pathological processes, encompassing embryo-
genesis, immune system function, inflammation, oncogenesis 
and tumor progression. To date, 44 different human chemo-
kines and 21 G protein-coupled chemokine receptors have been 
described.2,8
During the last two decades, the inhibition of chemokines 
or their receptors has been extensively explored—in preclinical 
models—as a strategy against autoimmune and chronic inflam-
matory diseases, including rheumatoid arthritis, systemic lupus 
erythematosus and Type 2 diabetes.9 Nowadays, some of these 
approaches have been translated into clinical trials (www.clini-
caltrials.gov). For instance, IL-8 receptor antagonists such as 
GSK1325756 and SB-656933,10 as well as anti-IL-8 monoclonal 
antibodies (ABX-IL8) are being tested in patients affected by 
chronic obstructive pulmonary disease or cystic fibrosis. MDX-
1100 (a fully human anti-CXCL10 monoclonal antibody)11 is 
currently under evaluation for the therapy of rheumatoid arthri-
tis and ulcerative colitis. Moreover, strategies for the inhibition 
of the chemokine receptor CCR2, including the monoclonal 
antibody MLN120212 and the PEGylated antisense oligonucle-
otide NOX-E3613 are being explored in Phase I/II clinical trials 
to treat multiple sclerosis and Type 2 diabetes, respectively. Of 
note, maraviroc (an allosteric inhibitor of CCR5 also known as 
Selzentry) is currently approved by FDA for HIV treatment, as 
CCR5 is an essential co-receptor for the cellular entry of most 
HIV strains.14
Opposed to the large number of preclinical and clinical 
studies evaluating chemokine inhibition as a strategy for auto-
immune disorders and chronic inflammation, only a few trials 
are evaluating the therapeutic potential of the modulation of 
the chemokine system in cancer patients (www.clinicaltrials.
gov). Vaccines based on autologous dendritic cells (DCs) genet-
ically modified to express CCL21 (a small member of the CC 
subfamily)15 are being investigated, either as single agents or in © 2012 Landes Bioscience.
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combination with CD40L-expressing DCs, against melanoma 
and lung carcinoma. MLN1202 is currently under investigation 
as a single agent in unspecified metastatic neoplasms. Moreover, 
the safety and efficacy of a monoclonal antibody that specifi-
cally targets the CCR2 ligand (CNTO888) is being tested in 
metastatic prostate cancer patients (as monotherapy) as well as 
in patients affected by unspecified solid tumors (in combina-
tion with doxorubicin, gemcitabine, paclitaxel + carboplatin, or 
docetaxel). Reflecting the important role played by its ligand 
(CCL12) in normal and malignant hematopoiesis,16 an anti-
CXCR4 monoclonal antibody (BMS-936564) is being admin-
istered to multiple myeloma patients, alone or in combination 
with lenalidomide, dexamethasone, or bortezomib, as well as 
to patients with multiple B-cell neoplasms. Along similar lines, 
the anti-CCL12 PEGylated antisense oligonucleotide NOX-
A12 is under investigation as a single agent to treat multiple 
myeloma or lymphocytic leukemia patients.
Hematopoietic Growth Factors
The group of hematopoietic growth factors includes more than 
25 cytokines that are required for the maintenance of hemato-
poietic stem cells, their proliferation, their differentiation into 
distinct hematopoietic lineages, as well as for the preservation of 
a stable equilibrium in the mature hematopoietic compartment. 
In addition to this homeostatic role, hematopoietins coordinate 
the organismal response to stimuli that require the expansion of 
specific hematopoietic cell lineages, (e.g., pathogen infection).17 
The spectrum of cells targeted by different hematopoietins can 
be large, such in the case of the granulocyte macrophage colony 
stimulating factor (GM-CSF), or relatively restricted, such in 
the case of erythropoietin (EPO). In both cases, hematopoi-
etins do not simply convey proliferative signals but also stimu-
late cell survival, differentiation, lineage commitment and the 
functional activation of mature cells.18
Table 1. Operational classification of cytokines
Family Subfamily Members Ref.
Chemokines
C subfamily XCL1, XCL2
2,8
CC subfamily
CCL1, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL13, CCL14, CCL15, CCL16, CCL17, CCL19, 
CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26, CCL27, CCL28
CXC subfamily CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, 
CXCL16, PPBP
CX3C subfamily CX3CL1
Hematopoietins
IL6ST - shared CLCF1, CNTF, CTF1, IL-11, IL-6, LIF, OSM
17,18
IL13RA1 - shared IL-4, IL-13
IL12RB1 - shared IL12A, IL23A
IL3RB1 - shared GM-CSF, IL-3, IL-5
ILRG - shared IL-2, IL-4, IL-7, IL-9, IL-15, IL-21
Others G-CSF, EPO, GH1, GH2, LEP, PRL, TSLP, TPO
IL-1s IL-1A, IL-1B, IL-18 43
IL-10s IL-10, IL-19, IL-20, IL-22, IL-24, IL-28A, IL-28B, IL-29 61
IL-17s IL-17A, IL-17B, IL-17C, IL-17D, IL-17E, IL-17F 73
IFNs IFNα1, IFNα2, IFNβ1, IFNε1, IFNγ, IFNκ, IFNω 81–83
PDGFs M-CSF, EGF, FLT3L, HGF, KITL, PLEKHQ1, PGDFA-D, VEGFA-D 89,90
TGFβs AMH, BMP2, BMP7, GDF5, INHBA, INHBB, INHBC, INHBE, TGFβ1, TGFβ2, TGFβ3 103–106,108
TNFs
CD40L, EDA, FASL, LTA, LTB, RANKL, OX40L, TNF, TNFSF7, TNFSF8, TNFSF9, TNFSF12, 
TNFSF13, TNFSF13B, TNFSF14, TNFSF18, TRAIL
111–113
Abbreviations: AMH, anti-Mullerian hormone; BMP, bone morphogenetic protein; CD40L, CD40 ligand; CLC, cardiotrophin-like cytokine factor; CNTF, 
ciliary neurotrophic factor; CTF, cardiotrophin; EDA, ectodysplasin A; EGF, epidermal growth factor, EPO, erythropoietin; FASL, FAS ligand; FLT3L, FLT3 
ligand; GDF, growth differentiation factor preproprotein; GH, growth hormone; G-CSF, granulocyte colony stimulating factor; GM-CSF, granulocyte 
macrophage colony stimulating factor; HGF, hepatocyte growth factor; IFN, interferon; IL, interleukin; INHB, inhibin β; INHBE, activin β E; KITL, KIT 
ligand; LEP, leptin; LIF, leukemia inhibitory factor; LT, lymphotoxin; M-CSF, macrophage colony stimulating factor; OSM, oncostatin M, OX40L, OX40 
ligand; PDGF, platelet-derived growth factor; PLEKHQ, PH domain-containing protein; PPBP, pro-platelet basic protein; PRL, prolactin; RANKL, RANK 
ligand; TGFβ, transforming growth factor β, TNF, tumor necrosis factor; TPO, thrombopoietin; TSLP, thymic stromal lymphopoietin, VEGF, vascular 
endothelial growth factor.
Table 2. Currently approved cytokines for oncological indications*
Agent Commercial names Oncological indications
IFNα2b Intron A, Roferon-A Cervical intraepithelial neoplasia, CML, FL, HCL, melanoma, MM
IL-2 Aldesleukin, Proleukin Metastatic melanoma, metastatic renal cell carcinoma
Abbreviations: CML, chronic myeloid leukemia; FL, follicular lymphoma, HCL, hairy cell leukemia, IFN, interferon; IL, interleukin; MM, multiple myeloma. 
*by FDA or European Medicines Agency (EMA) at the day of submission.© 2012 Landes Bioscience.
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At present, several hematopoietic growth factors including 
EPO (Epogen, Procrit), IL-2 (Aldesleukin, Proleukin), granulo-
cyte colony stimulating factor (G-CSF, Filgastrim) and GM-CSF 
(Sargramostim, Molgramostim) are approved by FDA for the 
treatment of hematological deficiencies including anemia, neu-
tropenia and thrombocytopenia.19,20 Although these conditions 
are highly relevant in oncological settings, as they often develop 
as dose-limiting side effects of chemotherapy, we will not dis-
cuss here clinical trials in which hematopoietins are employed (1) 
to prevent/ameliorate post-chemotherapy cytopenia; and (2) to 
facilitate immune reconstitution upon bone marrow transplanta-
tion. Rather, we will focus our discussion on the modulation of 
hematopoietins to obtain specific immunostimulatory or direct 
anticancer effects.
Besides being employed to boost the proliferation of hema-
topoietic cells, especially in protocols of adaptive cell transfer,21 
IL-2 is currently approved by FDA to treat immunosensitive 
tumors such as melanoma and renal cell carcinoma (RCC) 
(Table 2). In line with this notion, IL-2 is also included in 
approximately 50 early (Phase I/II) clinical trials that evaluate 
various combination regimens for the therapy of melanoma and 
RCC. Furthermore, IL-2 is being extensively studied (19 Phase I/
II clinical trials) as an off-label (co-)medication against multiple 
hematological and solid malignancies, including breast cancer 
(4 trials) and neuroblastoma (2 trials) (Table 3). In 11 of these 
trials, unmodified recombinant human IL-2 (rhIL-2) is used, 
while 7 others employ IL-2 fused to a tumor-targeting peptide 
(such as the recombinant antibody fragments F16 or L19).22,23 In 
a rather peculiar approach, the safety and efficacy of an attenu-
ated strain of Salmonella typhimurium genetically engineered to 
express human IL-2 are being investigated in patients with unre-
sectable hepatic metastases from a solid tumor. In a few cases, 
IL-2-based chimeras are tested as single agents. More often, IL-2 
is co-administered with conventional chemotherapeutics or anti-
cancer vaccines (www.clinicaltrials.gov).
G-CSF and GM-CSF stimulate the differentiation of bone 
marrow stem cells toward the granulocytic (both G-CSF and 
GM-CSF) and monocytic (GM-CSF only) lineages.20 In addi-
tion, G-CSF promotes the mobilization of hematopoietic pre-
cursor cells from the bone marrow into the bloodstream.24 Since 
their approval by FDA (in the early 1990s), G-CSF and GM-CSF 
have been used in millions of cancer patients to prevent/coun-
terbalance chemotherapy-associated neutropenia.20 Moreover, 
G-CSF has been tested for its ability to “prime” leukemic cells 
and hence render them more sensitive to conventional chemo-
therapy. However, results from a large randomized clinical trial 
indicate that G-CSF priming might extend disease-free (but not 
overall) survival, and only in patients with standard-risk acute 
myeloid leukemia.25 Today, G-CSF and GM-CSF are employed 
in no less than 100 clinical trials, often, if not always, in combi-
nation with therapeutic strategies that are known (or expected) to 
provoke leucopenia. Multiple studies are testing G-CSF in com-
bination with plerixafor (a derivative of bicyclam with immuno-
stimulatory functions)26 for mobilizing hematopoietic cell stem 
cells prior to autologous transplantation. Moreover, GM-CSF is 
being used extensively in the context of anticancer vaccine-based 
clinical trials, either as a recombinant product (Sargramostim, 
Molgramostim) or upon genetic engineering of (re-)infused cells. 
Nevertheless, no clinical studies are currently testing whether 
G-CSF and GM-CSF might exert anticancer effects independent 
of their capacity to stimulate early hematopoiesis (www.clinical-
trials.gov).
IL-4 stimulates the differentiation of naive helper T cells into 
Th2 cells, in turn producing additional IL-4 as well as IL-10 
(see below) and IL-13.27 As it drives the local secretion of mito-
genic cytokines, the Th2 response has been suggested to promote 
tumor growth.28 In line with this notion, no trials are currently 
investigating the efficacy of IL-4 and IL-13 as anticancer agents. 
Nevertheless, as tumor cells often overexpress the IL-4 and/or the 
IL-13 receptor,29 IL-4 and IL-13 are being tested as tumor-target-
ing partners for the enzymatically active portion of Pseudomonas 
aeruginosa exotoxin A (Table 3).
Besides participating in the acute phase response at the 
organismal level,3,4 IL-6 can function as a paracrine regulator of 
inflammation and immunity.30 Moreover, some neoplasms (e.g., 
most variants of multiple myeloma) produce high levels of IL-6, 
and these are strictly required for tumor survival.31 Driven by 
promising preclinical observations,32 several monoclonal anti-
bodies that specifically block IL-6 have been tested in cancer 
patients during the last decade.31 Nevertheless, the actual efficacy 
of these drugs for oncological indications remain unclear.33,34 
One notable exception is represented by siltuximab (CNTO 328) 
for ovarian cancer patients experiencing paraneoplastic thrombo-
cytosis.35 The efficacy of siltuximab for oncological indications is 
currently being tested in no less than 15 Phase I/II clinical trials 
(www.clinicaltrials.gov).
IL-7 is a potent hematopoietic growth factor, stimulating the 
differentiation of hematopoietic stem cells into lymphoid progen-
itors as well as the proliferation of mature cells of the lymphoid 
lineage.36 In spite of early concerns on the possibility that IL-7 
might per se sustain hematopoietic tumorigenesis,37 IL-7 is now-
adays being investigated in the clinic, in both non-oncological 
(e.g., in HIV patients in combination with conventional antiret-
roviral drug) and oncological settings (Table 3). In particular, 
IL-7 is being tested either as a single agent in metastatic breast 
cancer patients (mainly to contain lymphopenia and divpenia, 
i.e., a severe restriction in the TCR repertoire, but also to stimu-
late an anticancer immune response)38 or in combination with 
vaccines against RCC, various types of sarcoma or neuroblas-
toma (www.clinicaltrials.gov).
Besides being involved in the differentiation of naive T cells, 
IL-12 potently stimulates the functions of T and natural killer 
(NK) cells. In particular, it promotes the secretion of TNFα and 
IFNγ and inhibits the generation of IL-4, de facto stimulating 
a cytotoxic Th1 response.39 In line with this notion, multiple 
distinct approaches for employing IL-12 in anticancer therapy 
are being evaluated (Table 3). Thus, in 4 Phase I/II clinical tri-
als, rhIL-12 is used in combination with cetuximab (a mono-
clonal antibody targeting the epidermal growth factor receptor, 
EGFR) or other cytokines (IL-2 + GM-CSF, delivered with 
microspheres) in head and neck cancer patients, as well as to 
boost vaccine-driven anticancer responses in melanoma or breast © 2012 Landes Bioscience.
Do not distribute.
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cancer patients. As an alternative, the IL-12-encoding gene is 
administered either via plasmid electroporation (to melanoma 
and Merkel cell carcinoma patients), either with a replication-
incompetent adenoviral strain (to melanoma and metastatic 
breast cancer patients), either within a non viral vector, alone 
or combined with chemotherapeutics (to colorectal, ovarian 
and primary peritoneal carcinoma patients), or in the context 
of adoptive cell transfer immunotherapy with genetically-engi-
neered tumor-infiltrating lymphocytes (www.clinicaltrials.gov).
Similar to IL-12, both IL-15 and IL-21 regulate the prolif-
eration and activation of NK and T cells.40,41 Moreover, IL-15 
has been shown to promote the survival of a specific subset of 
memory CD8+ T cells.42 Besides a few studies in which rhIL-
15 is being tested for its ability to stimulate the immune sys-
tem in HIV+ patients, there are 8 Phase I/II clinical trials in 
which the safety and efficacy of IL-15 and IL-21 is tested in 
oncological indications (Table 3). In six studies, rhIL-15 and 
rhIL-21 are given, either as standalone medications or combined 
with targeted anticancer agents, to patients with immunosensi-
tive neoplasms like melanoma and RCC. Alternatively, IL-15 is 
administered to boost the immune function of freshly infused 
NK cells, in an adoptive cell transfer approach, or used to engi-
neer DCs for the generation of an efficient vaccine against mela-
noma (www.clinicaltrials.gov).
Table 3. Clinical trials* on hematopoietins in cancer therapy (main trends)
Hematopoietin Agent Tumor type Trials* Phase Notes Refs.
IL-2
ALT801 Metastatic urothelial cancer 1 I-II
Combined with cisplatin and 
gemcitabine
NCT01326871
CD40L/IL-2-expressing 
tumor cell vaccine
B-CLL 1 I As single agent NCT00609076
DI-Leu16-IL2  
immunocytokine
Hematological neoplasms 1 I Combined with rituximab NCT00720135
F16IL2  
immunocytokine
Breast cancer 1 I-II Combined with paclitaxel NCT01134250
Breast cancer  
Solid tumors
1 I-II Combined with doxorubicin NCT01131364
hu14.18-IL2  
immunocytokine NB 1 II
Combined with GM-CSF and 
isotretinoin
NCT01334515
rhIL-2
AML 1 II Combined with famotine NCT01289678
Breast cancer 1 II
Combined anastrozol, 
aromasin, femar, pulsed DCs 
and thymosin 1α
NCT00935558
MDS 1 I-II
Combined with azacitidine
and ceplene
NCT01324960
Melanoma 1 II Combined with anticancer 
vaccine
NCT00784524
Metastatic breast cancer 1 II NCT00784524
NB 1 I
Combined with zoledronic 
acid
NCT01404702
NHL 1 II Combined with rituximab NCT00994643
Plasma cell neoplasms 1 II
Combined with anticancer 
vaccine
NCT00616720
Various metastatic 
neoplasms
1 I
Combined with 
cyclophosphamide and 
anticancer vaccine
NCT00676949
IL-2-expressing 
bacteria
Liver cancer 1 I As single agent NCT01099631
L19IL2 
immunocytokine
Advanced solid tumors 1 I-II As single agent NCT01058538
Pancreatic cancer 1 I-II Combined with gemcitabine NCT01198522
Microsphere delivery HNC 1 n.a.
Combined with GM-CSF and 
IL-12
NCT00899821
IL-4 IL-4PE Glioblastoma 1 II As single agent NCT00797940
IL-7
rhIL-7
NB Sarcoma 1 I-II
Combined with anticancer 
vaccine
NCT00923351
Metastatic breast cancer 1 II As single agent NCT01368107
MGN1601 RCC 1 I-II
Genetically modified 
anticancer vaccine
NCT01265368
Abbreviations: AML, acute myeloid leukemia; B-CLL, B-cell chronic lymphocytic leukemia; CD40L, CD40 ligand; DC, dendritic cell; FOLFIRI, folinic acid, 
5-fluorouracil, irinotecan; FOLFOX, folinic acid, 5-fluorouracil, oxaliplatin; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte macro-
phage colony-stimulating factor; HNC, head and neck cancer; IL-, interleukin; MDS, myelodysplastic syndrome; RCC, renal cell carcinoma; NB, neuro-
blastoma; NHL, non-Hodgkin lymphoma; p, plasmid-encoded; NK, natural killer; rh, human recombinant; TIL, tumor infiltrating lymphocyte. *Started 
after January 1, 2008 and not terminated at the day of submission.© 2012 Landes Bioscience.
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Interleukin-1 Family Members
The IL-1 family of cytokines includes three members: IL-1α, 
IL-1β and IL-18. IL-1-like proteins are mainly produced by acti-
vated macrophages, and play a prominent role in local and sys-
temic inflammation.43 IL-1 family members are synthesized as 
inactive precursors and are cleaved by intracellular proteases (pro-
IL-1α mainly by calpains, pro-IL-1β and pro-IL-18 mainly by 
the caspase-1-containing complex called inflammasome) before 
secretion.44-46 So far, two distinct types of monomeric IL-1 recep-
tors and one heteromeric IL-18 receptor have been identified, all 
belonging to the immunoglobulin superfamily.47,48 Of note, while 
the type I IL-1 receptor (IL1R1) is biologically active and trans-
duces IL-1 signals, the type II receptor (IL1R2) often acts as a 
soluble decoy receptor.49,50 Moreover, IL-1α and IL-1β are func-
tionally antagonized by the IL-1 receptor antagonist (IL-1RA), 
a soluble factor that binds non-productively to IL-1 receptors.51
Blockade of IL-1β signaling with specific monoclonal anti-
bodies or with a recombinant derivative of IL-1RA (anakinra) 
compromises the therapeutic effects of anthracyclines and oxali-
platin in immunocompetent, but not immunodeficient, mouse 
models.52,53 This suggests that IL-1β plays a key role in chemo-
therapeutic responses by virtue of its immunostimulatory func-
tions. Probably due to such a potent pro-inflammatory profile, 
correlating with a high risk for severe side effects, the adminis-
tration of recombinant IL-1 to cancer patients has not yet been 
tested. Conversely, the inhibition of IL-1 signaling with anakinra 
is being extensively tested, with encouraging results, in patients 
affected by Type 2 diabetes and many other autoimmune disor-
ders (www.clinicaltrials.gov).54-56
Results from a recent Phase II trial evaluating the safety and 
efficacy of rhIL-18 (SB-485232) in metastatic melanoma patients 
suggest that SB-485232 is safe but has limited anticancer activ-
ity as a single agent.57 Nowadays, SB-485232 is being tested, 
alone or in combination with doxorubicin, in patients affected 
by epithelial ovarian cancers (Phase I, NCT00659178) (www.
clinicaltrials.gov), but the results of these trials have not yet been 
published. Intriguingly, in spite of its potent pro-inflammatory 
Table 3. Clinical trials* on hematopoietins in cancer therapy (main trends) (continued)
Hematopoietin Agent Tumor type Trials* Phase Notes Refs.
IL-12
Ad-IL-12 Metastatic breast cancer 1 I As single agent NCT00849459
Ad-RTS-hIL-12 Melanoma 1 I
Combined with activator 
ligand
NCT01397708
EGEN-001
CRC 1 I-II
Alone or combined with 
FOLFIRI or FOLFOX
NCT01300858
Reproductive tract cancer
1 I Combined with doxorubicin NCT01489371
1 II As single agent NCT01118052
rhIL-12
Breast cancer 1 I-II
Combined with DC/tumor cell 
fusion vaccine
NCT00622401
Melanoma 1 II
Combined with daclizumab 
and anticancer vaccine
NCT01307618
SCC 1 I-II Combined with cetuximab NCT01468896
IL-12-expressing TILs Metastatic melanoma 1 I-II
Combined with 
cyclophosphamide, 
fludarabine and G-CSF
NCT01236573
Microsphere delivery HNC 1 n.a.
Combined with GM-CSF and 
IL-2
NCT00899821
NHS-IL12
Epithelial and mesenchimal 
malignancies
1 I As single agent NCT01417546
pIL-12
Melanoma 1 II
As single agent
NCT01502293
Merkel cell cancer 1 II NCT01440816
IL-13 IL13-PE38QQR Brain tumors 1 I As single agent NCT00880061
IL-15
IL-15-expressing DCs Melanoma 1 I-II Autologous DC-based vaccine NCT01189383
rhIL-15
Metastatic cancer 1 I
As single agent
NCT01572493
Metastatic melanoma 
Metastatic RCC
1 I NCT01021059
IL-15-activated NK cells
Pediatric refractory solid 
tumors
1 I-II
Combined with haploidentical 
stem cell transplantation
NCT01337544
IL-21 rhIL-21
Melanoma 2 I Combined with ipilimumab NCT01489059
II
As single agent
NCT01152788
Metastatic melanoma 1 II NCT00601861
RCC 1 I-II NCT00617253
Abbreviations: AML, acute myeloid leukemia; B-CLL, B-cell chronic lymphocytic leukemia; CD40L, CD40 ligand; DC, dendritic cell; FOLFIRI, folinic acid, 
5-fluorouracil, irinotecan; FOLFOX, folinic acid, 5-fluorouracil, oxaliplatin; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte macro-
phage colony-stimulating factor; HNC, head and neck cancer; IL-, interleukin; MDS, myelodysplastic syndrome; RCC, renal cell carcinoma; NB, neuro-
blastoma; NHL, non-Hodgkin lymphoma; p, plasmid-encoded; NK, natural killer; rh, human recombinant; TIL, tumor infiltrating lymphocyte. *Started 
after January 1, 2008 and not terminated at the day of submission.© 2012 Landes Bioscience.
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profile, IL-18 has recently been shown to suppress metastasis sur-
veillance by NK cells.58 In line with this notion, elevated levels of 
circulating IL-18 have been associated with poor disease outcome 
in pancreatic and lung cancer patients.59,60 Taken together, these 
observations suggest that the administration of SB-485232 may 
be beneficial to patients affected by specific neoplasms (such as 
melanoma) but detrimental in others.
Interleukin-10 Family Members
According to current classifications, nine cytokines belong to the 
IL-10 family: IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28A, 
IL-28B and IL-29.61 With the notable exception of IL-24,62 these 
proteins operate through heteromeric receptors that share the 
IL-10 receptor β subunit.63,64 Nevertheless, the biological out-
comes of IL-10 family members are extremely heterogeneous, 
encompassing consistent immunosuppression (such as that trig-
gered by IL-10),65 the induction of an antiviral state (by IL-28A, 
IL-28B and IL-29, which are also known as Type III IFNs),66 
as well as (often STAT3-dependent) mitogenic and pro-survival 
effects (by IL-19, IL-20, IL-22 and IL-26).67 Of note, Il10-/- mice 
develop a chronic and fatal enterocolitis, which can be stopped 
by administration of IL-10.68 In line with the potent immuno-
suppressive functions of IL-10, early clinical trials were launched 
to study the safety and efficacy of rhIL-10 in patients affected 
by psoriasis and psoriatic arthritis.69 Following the encouraging 
results of these studies, rhIL-10 (nowadays produced under the 
name of prevascar or ilodecakin) is being tested in other clini-
cal settings featuring excessive/chronic inflammation, including 
wound healing and ulcerative colitis (in the latter scenario, IL-10 
is produced in situ by genetically engineered Lactococcus lactis). 
In addition, a humanized anti-IL-10 antibody (SCH708980) is 
under investigation as an anti-immunosuppressive agent during 
visceral Leishmaniasis. Of note, there are no ongoing clinical tri-
als that evaluate the therapeutic potential of cytokines from the 
IL-10 family (or their inhibitors) in cancer patients (www.clini-
caltrials.gov). This said, there is a vast literature that correlate 
elevated serum levels of IL-10 with poor prognosis in multiple 
hematological and solid malignancies,70-72 suggesting that—at 
least in some patients—the inhibition of IL-10 may turn out to 
be therapeutically beneficial.
Interleukin-17 Family Members
So far, six different IL-17 variants have been described 
(IL-17A-F).73As a family, IL-17 (which is most often secreted by 
helper T cells in response to IL-23) exerts potent pro-inflamma-
tory functions, stimulating the release of many other cytokines 
(such as IL-1β, IL-6, GM-CSF, TGFβ and TNFα), chemokines 
(e.g., MCP-1), and prostaglandins (e.g., PGE2).74 IL-17 family 
members operate by binding to a heterodimeric receptor, which 
can be assembled by 2 out of 5 different subunits (IL17RA-E).75 
The exact role of IL-17 and IL-17-producing helper T (Th17) cells 
in tumor progression and response to therapy is controversial.76 
On one hand, IL-17-secreting γδ T cells that arise in response 
to IL-1β + IL-23 appear to be required for optimal therapeutic 
responses, presumably due to the fact that they are prone to 
secrete GM-CSF and IFNγ.52,53 On the other hand, Th17 cells 
that differentiate in the presence of TGFβ and IL-6 produce 
IL-17 and IL-10, de facto exerting immunosuppressive effects.77 
Hence, there are no ongoing clinical trials that evaluate the thera-
peutic potential of this cytokine in oncological settings (www.
clinicaltrials.gov). Conversely, monoclonal antibodies targeting 
IL-17A (ixekizumab and secukinumab) or IL17RA (brodalumab) 
have given encouraging results for the treatment of diseases with 
an auto-immune component such as uveitis, rheumatoid arthritis 
and psoriasis.78-80 Ixekizumab (also known as LY2439821) is cur-
rently being tested in a few clinical trials to optimize dosage and 
administration schedules (www.clinicaltrials.gov).
Interferons
Interferons (IFNs) have first been characterized for their abil-
ity to “interfere” with viral replication, and indeed one of their 
major functions is the establishment of a robust antiviral state in 
response to infection.81 In addition, IFNs activate immune cells 
and facilitate the recognition of tumor cells by the immune sys-
tem as they stimulate antigen presentation to T lymphocytes.82 
IFNs are usually subdivided into three classes: Type I (including 
IFNα, IFNβ and IFNω), Type II (in humans: IFNγ), and Type 
III IFNs (including IL-28A, IL-28B and IL-29, see above). Type 
I IFNs signal through a receptor complex known as the IFNα 
receptor (IFNAR), consisting of IFNAR1 and IFNAR2 chains. 
Along similar lines, IFNγ functions by binding to a heterodi-
meric IFNγ receptor (IFNGR), which consists of IFNGR1 and 
IFNGR2 chains.83 Recent data indicate that both IFNAR and 
IFNGR are required for optimal responses to immunogenic che-
motherapy, at least in preclinical settings.84-86
During the last two decades, great efforts have been spent 
at optimizing strategies to modulate the IFN system. On one 
hand, humanized monoclonal antibodies specific for IFNγ (fon-
tolizumab) have been developed and tested in clinical settings. 
Thus, fontolizumab has been shown to be safe and clinically 
efficient in patients with chronic inflammatory pathologies such 
as rheumatoid arthritis or moderate to severe Crohn disease.87,88 
On the other hand, recombinant IFNα2b has been approved by 
FDA for a wide range of indications, including chronic hepatitis 
B and C, hairy cell leukemia, chronic myeloid leukemia, mul-
tiple myeloma, follicular lymphoma and malignant melanoma 
(Table 2). Nowadays, the efficacy of IFNα2 against cancer is 
being tested in 58 clinical trials, of which 22 evaluate IFNα2b 
in FDA-approved clinical settings (most often in melanoma 
patients). Of the remaining 36 studies, 12 investigate the thera-
peutic potential of IFNα2 in RCC patients, while the others span 
multiple solid and hematopoietic neoplasms, including bladder 
cancer, hepatocellular carcinoma, colorectal carcinoma, meso-
thelioma, pancreatic cancer and Hodgkin lymphoma (Table 4). 
Frequently (11/58 trials), IFNα2 is tested as monotherapy. As an 
alternative, combination regimens with bevacizumab (7/58 tri-
als), dacarbazine (3/58 trials), cisplatin (3/58 trials), cyclophos-
phamide (2/58 trials), sorafenib (2/58 trials) or decitabine (2/58 
trials) are being investigated. Of note, a relatively high proportion © 2012 Landes Bioscience.
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Table 4. Clinical trials* on IFNs as anticancer agents (main trends)
Chemokine Tumor type Trials* Phase Notes Ref.
Early clinical trials (Phase I-II)
IFNα
Adult T-cell leukemia/
lymphoma
1 n.a. Combined with valproic acid and zidovudine NCT00854581
Advanced solid tumors
1 I Combined with decitabine NCT00701298
1 I
Combined with cyclophosphamide  
and vinorelbine
NCT00908869
1 I
Combined with sodium stibogluconate
NCT00629200
1 II NCT01479309
Bladder cancer 1 II As single agent NCT01162785
Cervical cancer 1 II Combined with radiotherapy and RA NCT01276730
CML 3
I Combined with nilotinib NCT01294618
II
As single agent NCT01392170
Combined with nilotinib NCT01220648
CRC 1 I-II Combined with celecoxib and poly-ICLC NCT01545141
Cutaneous T-cell 
lymphoma
1 n.a. Combined with UV light NCT00724061
HCC 1 I As single agent NCT00838968
Hodgkin lymphoma 1 II Combined with ABVD NCT01404936
Kidney cancer
1 I-II Combined with radioablation NCT00891475
1 I-II Combined with pazaponib NCT01513187
1 II Combined with sorafenib NCT00589550
4 II Combined with bevacizumab
NCT00619268 NCT00719264 
NCT00796757 NCT00873236
1 II Combined with celecoxib NCT01158534
1 II Combined with GM-CSF and IL-2 NCT01176552
1 II Combined with bevacizumab and IL-2 NCT01274273
Malignant pleural 
mesothelioma
2 I
Combined with cisplatin and pemetrexed NCT01119664
As single agent NCT01212367
NHL 1 II
In alkylating agent- or anthracycline-based 
regimens plus rituximab
NCT00842114
Neurofibroma 1 II As single agent NCT00678951
Pancreatic cancer 2 I
Combined with 5-FU, cisplatin and gemcitabine NCT00660270
Combined with 5-FU, docetaxel,  
gemcitabine and oxaliplatin
NCT00761241
Various solid tumors 1 II
Combined with DC- and TIL-based 
immunotherapy plus cyclophosphamide  
and TNFα
NCT00610389
IFNγ
CRC 1 II
Combined with bevacizumab,  
5-FU and folinic acid
NCT00786643
Melanoma
1 n.a. Combined with peptide-based vaccine NCT00977145
1 I-II Combined with TIL and IL-2 NCT01082887
Plasma cell neoplasms 1 II Combined with antitumor vaccine NCT00616720
Soft tissue sarcoma 1 II
Combined with autologous NY-ESO-1-specific 
CD8+ T cells, cyclophosphamide and IL-2
NCT01477021
Advanced clinical trials (Phase III-IV)
IFNα
Bladder cancer 1 III Combined with BCG, epirubicin and mitomycin C NCT01094964
CRC 1 III Combined with 5-FU and folinic acid NCT01060501
HCV-associated HCC 1 IV Combined with ribavirin NCT00834860
Kidney cancer 1 III
Combined with bevacizumab
NCT00738530
Urogenital cancer 1 III NCT00631371
Abbreviations: 5-FU, 5-fluorouracil; ABVD, bleomycin, dacarbazine, doxorubicin, vinblastine; BCG, bacillus Calmette-Guérin; CML, chronic myeloid leukemia; 
CRC, colorectal carcinoma; DC, dendritic cell; GM-CSF, granulocyte macrophage colony stimulating factor; HCC, hepatocellular carcinoma; HCV, hepatitis 
C virus; IFN, interferon; IL, interleukin; n.a., not available; NHL, Non-Hodgkin’s lymphoma; RA, retinoic acid; RCC, renal cell carcinoma; TIL, tumor infiltrating 
lymphocyte; TNF, tumor necrosis factor; UV, UV. *Started after January 1, 2008 and not terminated at the day of submission.© 2012 Landes Bioscience.
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of IFNα2-based clinical trials (around 20%) consists of advanced 
studies (Phase III/IV), presumably reflecting the limited safety 
issues associated with the use of a FDA-approved molecule. At 
present, rhIFNγ (which is approved by FDA for the therapy of 
granulomatous disease and severe osteopetrosis) is being tested 
against a wide range of cancer-unrelated pathologies, including 
infections and inflammatory diseases. Moreover, there are five 
ongoing clinical studies that evaluate the safety and efficacy of 
IFNγ in oncological indications. In one case, IFNγ is used alone 
or in combination with bevacizumab, 5-fluorouracil and folinic 
acid against colorectal cancer. In the others, IFNγ is employed to 
boost anticancer immune responses driven by the administration 
of autologous T cells or peptide vaccines (in patients affected by 
soft tissue sarcoma, melanoma or plasma cell neoplasms) (www.
clinicaltrials.gov).
PDGF Family Members
The PDGF family of cytokines includes four PDGF isoforms 
(PDGFA-D), four isoforms of the vascular endothelial growth 
factor (VEGFA-D) and other six rather heterogeneous proteins. 
PDGFs, which activate cellular responses via two distinct tyrosine 
kinase receptors (PDGFRα and β), can be released by activated 
platelets, as well as smooth muscle cells, activated macrophages, 
and endothelial cells.89 PDGFs exert potent mitogenic functions 
over a plethora of distinct cell types and play an important role 
in development and angiogenesis.90 In line with this notion, 
PDGFRs are often hyperactivated in cancer, often due to point 
mutations in PDGFRA or PDGFRB, such as in the case of gas-
trointestinal stromal tumors (GISTs).91 The same holds true for 
other PDGF-like protein receptors including KIT (which delivers 
potent mitogenic signals and is mutated in more than 70% GIST 
patients),92 EGFR (which is overexpressed or mutated in colorectal 
and lung cancer)93 and FLT3 (which is frequently hyperactivated 
in acute myeloid leukemia patients).94 Along similar lines, tumor 
cells often overexpress VEGF, stimulating the so-called “angio-
genic switch,” i.e., the transition of a tumor mass from a non-
vascularized to a vascularized state.95 The FLT3 ligand (FLT3L) 
has been shown to expand DCs in vivo (in mice), resulting in the 
elicitation of NK-mediated antitumor effects.96,97 Nevertheless, 
given their potent mitogenic (and hence potentially tumorigenic) 
properties, it is not surprising that PDGF family members are not 
employed as immunostimulatory agents against cancer, neither 
alone nor in combination with other drugs. Rather, chemicals 
that selectively inhibit the tyrosine kinase activity of PDGFR, 
KIT and FLT3 (including imatinib, lapatinib and sorafenib), 
as well as monoclonal antibodies that specifically block EGFR 
(i.e., cetuximab, panitumumab) or VEGFA (i.e., bevacizumab), 
are currently approved by FDA for an ever-increasing number of 
oncological indications and are associated with consistent rates of 
remissions.98 These agents are the subject of an intense wave of 
clinical trials, aimed at finding new indications as well as at opti-
mizing dosage and administration schedules (www.clinicaltrials.
gov). The detailed discussion of such studies largely exceeds the 
scope of the present Trial Watch and can be found elsewhere.99 
This said, it is worth noting that several compounds that were 
developed to specifically target the receptors for PDGF family 
members, including imatinib and many others, are less specific 
than expected, and de facto exert potent off-target immunos-
timulatory effects.84,100,101 This property has raised great expecta-
tions and—as many of these agents have already been approved 
by FDA for anticancer therapy—will presumably be tested in the 
short future in appropriate clinical trials.
TGFβ Family Members
TGFβ1 has first been characterized for its ability to trigger the 
growth of normal rat kidney (NRK) fibroblast colonies in soft-
agar assays (though only if small amounts of EGF were present).102 
Since then, three distinct subtypes of human TGFβ have been 
identified (TGFβ1-3), together with at least additional eight pro-
teins that are now considered part of the TGFβ family, including 
polypeptides of the activin-inhibin hormonal system and at least 
two bone morphogenic proteins (BMP2 and BMP7).103 TGFβs 
signals are transduced intracellularly by homo- or heterodimeric 
serine/threonine kinase receptors, which can be assembled start-
ing from three distinct subunits (TGFBR1-3).104 In normal 
cells, TGFβs, and in particular TGFβ1, exert antiproliferative 
effects by upregulating the expression of cell cycle inhibitors 
such as p21CIP1 and p15INK4B or trigger cell death by activating 
SMAD- or DAXX-dependent apoptosis.105 Conversely, cancer 
cells often become refractory to the inhibitory effects of TGFβ 
and, at least in some cases, also overexpress it.106 In this setting, 
TGFβ stimulates angiogenesis and facilitates the conversion of 
effector T lymphocytes into FOXP3+ immunosuppressive T cells 
(Tregs) or Th17 cells, de facto exerting pro-tumor functions.106,107 
Of note, BMP2 and BMP7 also activate the SMAD signaling 
pathway, yet mainly function as osteogenic mediators.108 Over 
the two last decades, two distinct monoclonal antibodies against 
TGFβ have been developed: metelimumab (CAT-192, which 
specifically targets TGFβ1) and fresolimumab (GC-1008, which 
can block TGFβ1-3).109 In people affected by systemic sclerosis, 
metelimumab was found to be safe but ineffective,110 leading the 
proprietary pharmaceutical company to focus on fresolimumab. 
Today, fresolimumab is being tested, alone or combined with 
other interventions, in pulmonary fibrosis, myelofibrosis and 
focal segmental glomerulosclerosis patients, as well as in patients 
affected by glioma, mesothelioma, melanoma and metastastic 
breast cancer (www.clinicaltrials.gov). To our knowledge, any 
other clinical trial is currently investigating the modulation of 
TGFβ signaling in oncological indications.
Tumor Necrosis Factors
The TNF family of cytokines includes more than 15 distinct pro-
teins, all of which can, at least in some settings, trigger cell death 
upon binding to specific transmembrane receptors.111-113 The 
best known member of the family, TNFα, has first been identi-
fied in 1975, thanks to the work of Lloyd Old at the Memorial 
Sloan-Kettering Cancer Center (New York).114 Another TNF, 
lymphotoxin (LT, also known as TNFβ), had been discovered 
a few years earlier, in 1968,115,116 but it was not until the cloning © 2012 Landes Bioscience.
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of TNFα and LT cDNAs, in 1985, that the homology between 
these two proteins became evident.117 TNFα can bind two dif-
ferentially expressed transmembrane receptors: while Type I 
TNFR (TNFR1) is found at the surface of virtually all cells, type 
II TNFR (TNFR2) is expressed only by cells of the immune 
system.113 TNFR1 ligation can induce biological outcomes as 
diverse as the activation of the NFκB system (which normally 
delivers pro-survival signals), the initiation of mitogen-activated 
protein kinase (MAPK)-transduced signaling cascades (which 
can regulate proliferation, differentiation and cell death), and the 
induction of cell death (via apoptosis or regulated necrosis).118,119 
The TNF family also includes FAS and CD40 ligands (FASL 
and CD40L, both exerting a major role in the development, 
homeostasis and function of the immune system),120,121 RANK 
ligand (RANKL, which has been involved in the differentiation 
of osteoclasts, in the maturation of DCs and in hormone-driven 
breast carcinogenesis),122-124 as well as TNF-related apoptosis-
inducing ligand (TRAIL).125
TNFα has been shown to play a crucial role in the pathogene-
sis of multiple inflammatory diseases, including (though presum-
ably not limited to) rheumatoid arthritis, Crohn disease, psoriasis, 
psoriatic arthritis, ankylosing spondylitis and juvenile idiopathic 
arthritis.126 During the past 20 y, a large battery of TNF inhibi-
tors has been developed and approved by FDA for the treatment 
of these conditions. Such agents include anti-TNFα monoclonal 
antibodies like infliximab (Remicade), adalimumab (Humira), 
certolizumab pegol (Cimzia), and golimumab (Simponi), as well 
as the artificial fusion protein etanercept (Enbrel), consisting in 
two soluble human TNFR moieties linked to the Fc portion of an 
IgG1.99,126 Denosumab (a fully human anti-RANKL antibody), is 
currently approved by FDA for the treatment of post-menopausal 
osteoporosis and for the prevention of skeletal-related events in 
patients with bone metastases from solid tumors (Table 2).127,128 
Furthermore, a monoclonal antibody that neutralizes the OX40 
ligand (OX40L, an important co-stimulatory molecule during 
immune responses) is currently being tested for the prevention of 
allergen-induced airway obstruction in adults with mild allergic 
asthma (www.clinicaltrials.gov).
In addition to these applications and studies (which do not 
directly relate to anticancer therapy), TNFα has been extensively 
employed in combination with melphalan (an alkylating agent) 
for isolated limb perfusion in metastatic melanoma and sarcoma 
patients,129 an approach associated with high rates of limb salvage 
but limited impact on overall survival.130,131 Moreover, there are 
22 ongoing clinical trials that evaluate whether the modulation of 
TNF family members is beneficial or not to cancer patients (www.
clinicaltrials.gov). Three of these 22 studies (all of which are in 
Phase I/II) investigate whether the administration of rhTNFα (as 
such or fused to a tumor-targeting antibody fragment)132 is effi-
cient (alone or in combination with doxorubicin or melphalan) in 
patients affected by lymphoma, melanoma or other advanced solid 
tumors (Table 5). Four clinical trials are testing whether monoclo-
nal antibodies that can activate the TRAIL receptor 1 (TRAILR1), 
de facto mimicking TRAIL cytotoxicity, exert therapeutic effects, 
if combined with other chemotherapeutics, against hematologi-
cal and solid tumors including cervical and colorectal carcinoma 
(Table 5). The safety and efficacy of strategies based on CD40L are 
being investigated in seven clinical trials. In this setting, CD40L 
is either introduced directly into the tumor by local injection of 
adenoviral vectors, or transfected into autologous DCs or cancer 
cells that are used to generate vaccines. In addition, CP-870,893 
(a monoclonal antibody that activates CD40, de facto mimicking 
CD40L) is tested, in combination with carboplatin and paclitaxel, 
in patients bearing advanced solid tumors (Table 5). Finally, deno-
sumab is currently under investigation (in nine Phase II/III clinical 
trials) for its capacity to prevent/treat bone metastase in patients 
affected by multiple myeloma and solid tumors including breast 
and prostate cancer (www.clinicaltrials.gov).
Table 5. Clinical trials* on TNFs and TNF-mimicking agents in anticancer therapy (main trends)
Chemokine Agent Tumor type Trials* Phase Notes Refs.
CD40L
CP-870,893 Metastatic solid tumors 1 I Combined with carboplatin and paclitaxel NCT00607048
rhCD40L
B-CLL 1 I
CD40L-expressing autologous tumor  
cell-based vaccine
NCT00609076
Bladder cancer 1 I-II Adenoviral gene therapy NCT00891748
Lung cancer 2 II
CD40L-expressing allogeneic tumor  
cell-based vaccine
NCT00601796
CD40L-expressing cell-based vaccines NCT01433172
MDS 1 I CD40L NCT00840931
Melanoma 1 I Adenoviral gene therapy NCT01455259
TNFα
L19TNFα
Advanced solid tumors 1 I-II As single agent NCT01253837
Melanoma 1 I Combined with melphalan NCT01213732
rhTNFα
Advanced solid tumors
Lymphoma
1 I Combined with doxorubicin NCT01490047
TRAIL
Conatumumab
Advanced hematological 
and solid tumors 2
II
Alone or combined with bevacizumab, 
FOLFOX and ganitumab
NCT01327612
Advanced solid tumors I-II Combined with AMG479 NCT00819169
Dulanermin CRC 1 I Combined with bevacizumab NCT00873756
Mapatumumab Advanced cervical cancer 1 I-II Combined with cisplatin and radiotherapy NCT01088347
Abbreviations: Ad, adenovirus; B-CLL, B-chronic lymphocytic leukemia; CRC, colorectal cancer; CD40L, CD40 ligand; DC, dendritic cell; FOLFOX, folinic 
acid, fluorouracil, oxaliplatin; MDS, myelodysplastic syndrome; MM, multiple myeloma, rh, recombinant human; TNF, tumor necrosis factor; TRAIL, TNF-
related apoptosis-inducing ligand. *Started after January 1, 2008 and not terminated at the day of submission.© 2012 Landes Bioscience.
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Concluding Remarks
Cytokines constitute a highly heterogeneous group of proteins 
that, taken together, regulate virtually all aspects of the cell 
biology. Some of them, such as GM-CSF, potently stimulate 
the replication and survival of hematopoietic cell precursors, 
and are mainly employed in tumor patients to help them 
reconstituting the hematopoietic system upon chemotherapy 
or transplantation. Others, including multiple members of 
the PDGF family, exert potent mitogenic functions and hence 
cannot be employed in cancer therapy, as they would stimu-
late, rather than prevent, oncogenesis and tumor progression. 
Finally, there are cytokines that have been approved by FDA (or 
are being clinically tested) for oncological indications, owing 
to their ability to stimulate anti cancer immune responses. 
For instance, IL-2 has been associated with consistent rates 
of tumor regression in melanoma and RCC patients,133,134 
probably because these malignancies are able to elicit per se ele-
vated levels of antitumor lymphocytes. Although the elevated 
pleiotropism of the cytokine system constitutes an obstacle for 
the development of highly targeted therapeutics (implying that 
these proteins may be intrinsically prone to elicit side effects), 
we surmise and hope that ongoing and/or future clinical tri-
als will lead to the approval of additional cytokines for use in 
humans against cancer.
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